Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Health Canada recently approved, for the first time in Canada, a clinical project for a Phase I study aimed at treating lymphomas associated with the Epstein-Barr virus (EBV) through adoptive cellular immunotherapy that is specific to EBV.

18 Jan 2016

Novel strategies on the way for difficult-to-treat head and neck cancer

Novel strategies are on the way for difficult-to-treat and advanced head and neck cancer, the most heterogeneous group of malignancies which are generally associated with poor survival, and encouraging results have been presented at the first ESMO Asia 2015 Congress in Singapore.

17 Dec 2015

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

Veloxis Pharmaceuticals A/S, today announced that Envarsus XR was granted Orphan Drug status by the U.S. Food and Drug Administration for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus XR received marketing authorization from the FDA on July 10, 2015.

14 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.

11 Jul 2015

Helmholtz Zentrum München scientists identify how Epstein-Barr virus conceals in human cells

Scientists at Helmholtz Zentrum München have now discovered how Epstein-Barr virus (EBV) conceals itself in human cells. A main culprit for its bad visibility by the immune system is the viral protein LMP2A. As published in the scientific journal PLOS Pathogens, the protein helps EBV-infected cells hide from T cells. This camouflage through the LMP2A protein may play a major role in the causation of cancer by EBV.

16 Jun 2015

Children who eat certain types of food more likely to contract Epstein-Barr virus

A new study by UNC Charlotte scholars is shedding light on the connection between diet and a common childhood disease.

9 Apr 2015

Funding helps researchers to kiss MS goodbye

Murdoch University researchers have received funding to investigate the link between the Epstein-Barr virus infection, more commonly known as glandular fever or the ‘kissing disease’, and the debilitating disease Multiple Sclerosis (MS).

24 Mar 2015

Funding helps researchers to kiss Multiple Sclerosis (MS) goodbye

24 Mar 2015

Study reveals functional heterogeneity of CD4 T cells in immune systems

Utilizing a novel transgenic mouse model, Edward Usherwood, PhD of Dartmouth's Norris Cotton Cancer Center and collaborators found that CD4 T cells divide into two different populations that each has a different job. One type performs antiviral functions, and the other survives life in the host.

23 Mar 2015

New method could lead to improved treatment for NPC patients

Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.

11 Mar 2015

High dose vitamin C therapy may have positive effect on Epstein-Barr virus infection

The Epstein-Barr virus (EBV) is a member of the herpes family that targets lymphocytes and epithelial cells. While the infection is usually benign, it can in some cases lead to acute infectious mononucleosis and can impair the immune system. EBV is also linked to several malignancies. There is currently no cure for removing EBV infections and very little success treating acute EBV infection and mononucleosis with drugs.

4 Jun 2014

UAMS receives $1.8M grant to lead new treatments for herpes viruses and cancers

A surprise discovery that could lead to new treatments for herpes viruses that infect more than 90 percent of the world's adult population has led to a $1.8 million grant to the University of Arkansas for Medical Sciences (UAMS) from the National Cancer Institute (NCI) at the National Institutes of Health (NIH).

5 May 2014

Researchers discover how STAT3 protein breaches antitumor mechanism prior to cancer development

A Stony Brook University-led international team of infectious disease researchers have discovered how a cellular protein, called STAT3, which is overactive in a majority of human cancers, interferes with an antitumor mechanism in cells and therefore promotes the growth of cancer.

18 Mar 2014

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”.

14 Jan 2014

Norwegian researchers map genetic variations associated with increased risk of MS and MG

The Norwegian researchers have taken part in an international cooperative effort to map 110 genetic variations that increase the risk of MS and MG. Most of these genetic variations have been mapped in recent years.

9 Jan 2014

Immunologists discover risk factor responsible for infectious mononucleosis in young people

More than 90 percent of all adults are carriers of the oncogenic Epstein-Barr Virus. Primary infection with this herpes virus as a young child is generally not linked to any symptoms, and usually offers life-long protection from its cancer-causing effect. However, for people who do not become infected with the virus until adolescence, the infection often leads to infectious mononucleosis (commonly known as glandular fever). Our immune systems can generally fend off this disease after a period of between one and several months. However, there is an increased risk of developing Hodgkin lymphoma at a later stage, a cancerous tumor of the lymphatic system.

20 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

Smoking influences survival of nasopharyngeal carcinoma patients

Survivors of nasopharyngeal carcinoma who are former or current smokers are more likely to have their disease progress, relapse, or spread, and are more likely to die of their disease, compared with survivors of nasopharyngeal carcinoma who have never smoked, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

21 Nov 2013

Mutations affecting immune system play important role in breast cancer

Mutations in the genes that defend the body against cancer-related viruses and other infections may play a larger role in breast cancer than previously thought, according to a study at the University of Illinois at Chicago.

19 Nov 2013

Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Novel strategies on the way for difficult-to-treat head and neck cancer

Envarsus XR granted FDA orphan drug designation for prophylaxis of organ rejection in kidney transplant patients

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Helmholtz Zentrum München scientists identify how Epstein-Barr virus conceals in human cells

Children who eat certain types of food more likely to contract Epstein-Barr virus

Funding helps researchers to kiss MS goodbye

Funding helps researchers to kiss Multiple Sclerosis (MS) goodbye

Study reveals functional heterogeneity of CD4 T cells in immune systems

New method could lead to improved treatment for NPC patients

High dose vitamin C therapy may have positive effect on Epstein-Barr virus infection

UAMS receives $1.8M grant to lead new treatments for herpes viruses and cancers

Researchers discover how STAT3 protein breaches antitumor mechanism prior to cancer development

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Norwegian researchers map genetic variations associated with increased risk of MS and MG

Immunologists discover risk factor responsible for infectious mononucleosis in young people

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Smoking influences survival of nasopharyngeal carcinoma patients

Mutations affecting immune system play important role in breast cancer

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in